EUVIMEDEUVIMED entdecken
FallberichtÜbersichtsarbeitOpen Access · CC BY 4.0

Primary thyroid diffuse large B-cell lymphoma: a case report and focused review of the literature

Kürsat Kirkgöz, Katja Weisel, Carsten Bokemeyer, Susanne von Kroge

Annals of Hematology · 09.10.2026 · 105 (11)

DOI: 10.1007/s00277-026-07303-7 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Annals of Hematology, online erschienen am 09.10.2026. Verfasst von Kürsat Kirkgöz und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, University Cancer Center Hamburg, University Medical Cent…. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Thyroid Neoplasms. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Primary thyroid diffuse large B-cell lymphoma (DLBCL) is a rare subset of primary extranodal DLBCL. Thus, there are limited evidence-based specific recommendations regarding its diagnosis and treatment. We present a case report of a patient with relapsed primary thyroid DLBCL, followed by a focused literature review covering key epidemiological, diagnostic, and therapeutic aspects. In 2017, a 74-year-old woman was diagnosed with primary thyroid non-GCB-type DLBCL (Ann Arbor IE, IPI 2) after presenting with dyspnoea, hoarseness, and cough. Treatment with R-CHOP and CNS prophylaxis achieved complete remission. Six years later, an isolated relapse occurred in the contralateral thyroid gland. The patient was treated with Pola-R-miniCHP (off-label), resulting in complete remission again. In the focused literature review core needle or surgical biopsy was found to be important for reliable histopathological characterization, while first-line treatment mainly consisted of rituximab-containing chemoimmunotherapy, occasionally combined with radiotherapy. Surgery was largely limited to diagnostic purposes. Reported 5-year overall survival rates ranged from 57% to 88%, whereas relapse or refractory disease and central nervous system involvement were rare. Registry-based studies, especially those focusing on primary extranodal DLBCL, are necessary to develop evidence-based treatment guidelines for these patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseThyroid NeoplasmsHumansFemaleAgedAntineoplastic Combined Chemotherapy ProtocolsRituximabPrednisoneDoxorubicinVincristineCyclophosphamide

Stichwörter der Autor:innen

Diffuse large B-cell lymphomaPrimary thyroid lymphomaThyroid

Substanzen

RituximabPrednisoneDoxorubicinVincristineCyclophosphamideR-CHOP protocol

Autor:innen und Institutionen

  • Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.
  • Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany. s.von…

Zitieren

APA

Kirkgöz, K., Weisel, K., Bokemeyer, C., & von Kroge, S. (2026). Primary thyroid diffuse large B-cell lymphoma: a case report and focused review of the literature. Annals of Hematology, 105(11). https://doi.org/10.1007/s00277-026-07303-7

Vancouver

Kirkgöz K, Weisel K, Bokemeyer C, von Kroge S. Primary thyroid diffuse large B-cell lymphoma: a case report and focused review of the literature. Annals of Hematology. 2026;105(11). doi:10.1007/s00277-026-07303-7

BibTeX
@article{Kirkgz2026,
  author = {Kirkgöz, Kürsat and Weisel, Katja and Bokemeyer, Carsten and von Kroge, Susanne},
  title = {Primary thyroid diffuse large B-cell lymphoma: a case report and focused review of the literature},
  journal = {Annals of Hematology},
  year = {2026},
  volume = {105},
  number = {11},
  doi = {10.1007/s00277-026-07303-7}
}
Kostenlos starten →